宫颈癌NY-ESO-1特异性T细胞免疫反应分析  

Analysis of the immune response of NY-ESO-1 specific T cells in cervical cancer

作　　者：袁源亮 刘凯[2,3,4] 冯亚宁 王若峥 YUAN Yuanliang;LIU Kai;FENG Yaning;WANG Ruozheng(The Third Clinical Medical College,Affiliated Tumor Hospital of Xinjiang Medical University,Urumqi 830011,China;Departments of Radiotherapy Center,Affiliated Tumor Hospital of Xinjiang Medical University,Urumqi 830011,China;Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi 830011, China;Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi 830011, China)

机构地区：[1]新疆医科大学第三临床医学院,乌鲁木齐830011 [2]新疆医科大学附属肿瘤医院放疗中心,乌鲁木齐830011 [3]新疆肿瘤学重点实验室,乌鲁木齐830011 [4]中国医学科学院肿瘤免疫与放疗研究重点实验室,乌鲁木齐830011

出　　处：《新疆医科大学学报》2020年第9期1136-1142,共7页Journal of Xinjiang Medical University

基　　金：国家自然科学基金(U1603282);中国医学科学院院外重点实验室建设项目(2018PT31050)。

摘　　要：目的探讨宫颈癌患者癌症-睾丸抗原(cancer-testis antigen,CTA)中纽约食管鳞状上皮癌抗原1(New York esophageal squamous cell carcinoma 1,NY-ESO-1)的特异性T细胞免疫应答及其临床相关性,为其在宫颈癌免疫治疗中的初步应用提供科学依据。方法收集新疆医科大学附属肿瘤医院2018年8月-2019年6月收治的31例宫颈癌初治患者,用合成的NY-ESO-1抗原重叠肽刺激宫颈癌患者的外周血单个核细胞(peripheral blood mononuclear cells,PBMCs),采用胞内细胞因子染色(intracellular cytokine staining,ICS)技术同时检测γ-干扰素(interferon-gamma,IFN-γ)等5种细胞因子,FlowJo10.6流式细胞软件分析宫颈癌患者外周血T细胞亚群胞内细胞因子分泌和共表达水平,再结合临床资料分析其与宫颈癌患者临床特征之间的关系。结果(1)宫颈癌患者外周血对NY-ESO-1抗原肽刺激产生免疫应答率为67.4%(21/31),其中CD4+T细胞免疫应答阳性率为32.3%(10/31),CD8+T细胞免疫应答阳性率为54.8%(17/31)。(2)宫颈癌NY-ESO-1特异性CD4+T细胞免疫反应频率中无流产史者(63.6%)明显高于有流产史者(15.0%),二者差异有统计学意义(P=0.018);宫颈癌NY-ESO-1特异性CD8+T细胞免疫反应频率中≤52岁者(70.6%)明显高于>52岁者(35.7%),二者统计学差异为临界值(P=0.052)。结论NY-ESO-1抗原肽能在宫颈癌患者外周血中产生特异性T细胞免疫反应。Objective To explore the specific T cell immune response and clinical relevance of New York esophageal squamous cell carcinoma antigen 1(NY-ESO-1)in cancer-testis antigen(CTA)of cervical cancer(CC)patients,to provide a scientific basis for its preliminary application in immunotherapy of cervical cancer.Methods A total of 31 newly diagnosed CC patients admitted to the Affiliated Tumor Hospital of Xinjiang Medical University from August 2018 to June 2019 were collected,and the peripheral blood mononuclear cells(PBMCs)of CC patients were stimulated with synthetic NY-ESO-1 antigen overlapping peptides,using intracellular cytokine staining(ICS)technology to simultaneously detect 5 kinds of cytokines such as interferon-gamma(IFN-γ)and FlowJo10.6 flow cytometry software to analyze intracellular cytokine secretion and co-expression levels of peripheral blood T cell subsets in patients with CC,combined with clinical data to analyze its relationship with the clinical characteristics of CC patients.Results(1)Peripheral blood of CC patients had an immune response rate of 67.4%(21/31)to NY-ESO-1 antigen peptide stimulation,of which CD4+T cell immune response positive rate was 32.3%(10/31)and CD8+T cell was 54.8%(17/31).(2)CC NY-ESO-1 specific CD4+T cell immune response frequency was significantly higher in the group with no history of miscarriage(63.6%)than in the group with a history of miscarriage(15.0%)(P=0.018);CC NY-ESO-1 specific CD8+T cell immune response frequency in the≤52-year-old group(70.6%)was significantly higher than that in the>52-year-old group(35.7%)and the statistical difference between the two groups is the critical value(P=0.052).Conclusion NY-ESO-1 antigen polypeptide can produce specific T cell immune responses in the peripheral blood of CC patients.

关 键 词：宫颈癌 NY-ESO-1 特异性T细胞免疫反应 胞内细胞因子染色 

分 类 号：R737.33[医药卫生—肿瘤]